Latest Therapies under investigation for multiple sclerosis Stories
Teva Pharmaceutical Industries Ltd.
arGentis Pharmaceuticals, LLC announced today that it has filed a patent application for Nucleic Acid Sequences highly associated with the inability of oral immune tolerance to be induced in some systemic sclerosis (SSc) patients.
Teva Pharmaceutical Industries and Antisense Therapeutics have announced that ATL/TV1102, a novel, anti-sense drug, significantly reduced disease activity in patients with relapsing-remitting multiple sclerosis.
Biogen Idec (NASDAQ: BIIB) announced today the pub
Teva Pharmaceuticals said a combination of Copaxone and antibiotic minocycline reduced brain lesions in patients with relapsing-remitting multiple sclerosis, compared to receiving Copaxone alone.
By Bill Berkrot NEW YORK (Reuters) - Teva Pharmaceutical Industries Ltd's multiple sclerosis (MS) drug Copaxone reduced relapses by 75 percent in both new patients and those who had not done well on the older Schering AG medicine Betaseron, according to a large study.
U.S. health officials cleared the way on Monday for multiple sclerosis drug Tysabri to return to the market with restrictions, following its withdrawal last year when it was linked to a rare but potentially fatal brain disease.
A high dose of Teva Pharmaceutical Industries Ltd.'s multiple sclerosis drug Copaxone is more effective at limiting relapses and brain lesions than the standard dose, without more side effects, researchers said on Wednesday.
WASHINGTON -- The government approved a drug Tuesday that tries a new method of attacking multiple sclerosis, an incurable disease of the central nervous system that affects 350,000 Americans. The drug -- a monoclonal antibody produced by Cambridge, Mass.- based Biogen Idec Inc.
FRIDAY, Nov. 26 (HealthDayNews) -- The U.S. Food and Drug Administration has approved Tysabri (natalizumab) as a new treatment for multiple sclerosis. The incurable nervous system disease affects about 350,000 Americans.
- To fire mitraille at.